Brief: Adverum Presents Data At Asgct Further Supporting Phase 2 Development Plans For ADVM-022
17/05/2022 21:51
May 17 (Reuters) - Adverum Biotechnologies Inc ADVM.O :
* ADVERUM PRESENTS DATA AT ASGCT FURTHER SUPPORTING PHASE 2
DEVELOPMENT PLANS FOR ADVM-022
* ADVERUM BIOTECHNOLOGIES INC - HUMAN EQUIVALENT ADVM-022
DOSE OF
6E10 VG/EYE PROVIDED THERAPEUTIC LEVELS OF AFLIBERCEPT IN NHPS
* ADVERUM BIOTECHNOLOGIES INC - ADMINISTRATION OF HUMAN
EQUIVALENT
DOSE OF 6E10 (3 X 10^10 VG/EYE DOSE IN NHP) WAS WELL TOLERATED
Source text for Eikon: ID:nGNX2fQ2wR
Further company coverage: ADVM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adverum Biotechnologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Adverum Reminds Stockholders To Tender Their Shares Into The Offer By Lilly
Brief: Adverum Biotechnologies Inc - Are-Nc Region No. 21 Llc Terminates Certain Lease Agreement With Adverum Biotechnologies - SEC Filing
Eli Lilly bets on eye care with buyout of gene therapy developer Adverum (updated)